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Abstract: The combination of brief chemo-radiotherapy provides high cure rates and
represents the first line of treatment for many lymphoma patients. As a result, a high
proportion of long-term survivors may experience treatment-related toxic events many
years later. Excess and unintended radiation dose to organs at risk (particularly heart, lungs
and breasts) may translate in an increased risk of cardiovascular events and second cancers
after a few decades. Minimizing dose to organs at risk is thus pivotal to restrain the risk of
long-term complications. Proton therapy, with its peculiar physic properties, may help to
better spare organs at risk and consequently to reduce toxicities especially in patients
receiving mediastinal radiotherapy. Herein, we review the physical basis of proton therapy
and the rationale for its implementation in lymphoma patients, with a detailed description of
the clinical data. We also discuss the potential disadvantages and uncertainties of protons that
may limit their application and critically review the dosimetric studies comparing the risk of
late complications between proton and photon radiotherapy.
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Introduction
Lymphomas are the most common hematologic malignancies worldwide and,
despite their different disease processes and histology, have a much more favorable
outcome than solid tumors. Particularly, combined chemo-radiotherapy cures most
Hodgkin’s lymphoma (HL) patients, with roughly 70–80% of them surviving many
decades after treatment.1–4 In contrast to HL, non-Hodgkin lymphomas (NHL) have
less favorable outcomes but, in general, survival rates in the long term are better
than those of most solid tumors.5 Given their favorable outcome, the reduction of
treatment-related toxic effects is the cornerstone of recent advances in the treatment
of HL and NHL. Specially, the likelihood of long-term survival raises the issue of
long-term complications, mostly related to latent radiation injuries from combined
curative treatments.6 In particular, long-term reports of large cohorts and national
registries have produced a strong evidence that the benefits from radiation may be
counterbalanced, decades later, by increased mortality and morbidity from cardio-
vascular events and second cancers.7–9 This evidence lead hematologists and
clinical oncologists to accept increased relapse rates as a barter for omitting radio-
therapy (RT) altogether.10,11 At the same time, efforts have been done from the
whole radiation oncology community to minimize RT-related complications to
organs adjacent to the target of treatment, particularly to thoracic organs at risk
(OARs) as breasts, heart, and lungs by reducing the prescribed RT dose and
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treatment fields without compromising cure rates.12 In
particular, the new concepts of involved-site RT (ISRT)
and involved-node RT (INRT) were recently developed for
the definition of smaller treatment volumes. Despite mar-
ginal differences, in both concepts, the pre-chemotherapy
disease involvement determines the clinical target volume,
resulting in greater sparing of OARs compared to the older
volumes.13 Proton therapy (PT), with its particular ballistic
characteristics favoring a low entrance dose and a step
fall-off of the dose at the end of the beam range (“Bragg
peak”), offers a great opportunity to further minimize the
risk of long-term complication related to photon-based
radiation while keeping the increased initial cure rate
offered by RT. However, PT requires a complex treatment
planning, is more expensive than photons and still suffers
from some uncertainties. For these reasons, the decision of
PT referral should always be driven by a dosimetric com-
parison with an optimally planned photon treatment in
order to demonstrate a clinical benefit for the patient, as
already carried out for other tumors.14 In this article, 1) we
review the ability of PT in reducing dose to organs at risk
with an overview of the current techniques for treatment
delivering and of the published clinical data, 2) we
describe the actual uncertainties which may limit its appli-
cation in lymphomas, 3) and we report a detailed summary
of the radiation dosimetry literature comparing PT and
photons.
Technical Aspects For Lymphomas
And Current Techniques In Delivering
Proton Therapy
Individualized treatment planning with PT is based on
various factors including patient-specific factors such as
age, gender, previous treatment, disease location, baseline
co-morbidities, and findings from initial disease extension,
evaluated with PET/CT scan. Modern radiation planning
using ISRT techniques requires appropriate image fusion
with functional (usually pretreatment/chemotherapy) ima-
ging to identify the initial sites of involvement.13,15,16
During the CT simulation (ideally with intravenous
contrast), for cases involving the mediastinum, a 4-dimen-
sional CT scan is often utilized to determine breathing
motion and the appropriate internal target volume (ITV)
margin. Also, the deep-inspiration breath-hold (DIBH)
technique can be used to reduce the breathing motion of
the mediastinum, thus narrowing the mediastinal target,
while minimizing the exposure of lung and heart.
Modern studies demonstrate that the lowest doses to the
nearby organs at risk are obtained for patients treated with
PT and DIBH (compared to photons), if clinically
available.17 Currently, there are various PT techniques
clinically available for cancer patients. This includes pas-
sive scattering technique and pencil beam scanning (PBS)
techniques.
Passive Scattering
Treatment planning goals for lymphomas with passive-
scattered proton beams are to irradiate the target with an
adequate dose while reducing the integral dose to the
patient, and the commonly utilized technique is the dou-
ble-scatter (DS) method. The relative size and heterogene-
ity of the targets can often present a challenge with the DS
techniques. Limitations of the passive-scattering delivery
technique include the following: field size (maximum),
inability to conform the dose proximally to the target,
and poor conformality distal to the target (compared to
spot scanning). Advantages to passive scattering delivery
include increased plan robustness to patient and target
motion uncertainties relative to PBS. With appropriate
margins and smearing techniques, passive scattering
plans are less sensitive to motion and density changes in
the beam path.
Most commonly, the treatment planning strategy for
passive-scattered PT is to assign the clinical target
volume (CTV) or ITV as the beam target. Many treat-
ment planning systems allow that margins be applied for
proton range uncertainties, distally and proximally,
directly in the properties of each beam. Various institu-
tions use a formula for inherent range uncertainties simi-
lar to that described by Moyers et al: (Margin = α %
Range + β mm, where α is related to uncertainties in
dose calculation).18 This margin accounts for various
factors including relative proton stopping power conver-
sion factor, beam-delivery reproducibility, treatment plan-
ning system commissioning accuracy, and compensator
design. The effects of setup errors on the proton range
are compensated by range compensator smearing (thin-
ning) calculated using Urie et al19. Additionally, collima-
tor margins for the lateral penumbra are set to the
planning target volume (PTV) or CTV with an adequate
expansion for setup variations. Appropriate margins can
be set to ensure target coverage along and perpendicular
to each beam. Uncertainties due to potential relative
biological effectiveness (RBE) variations along the
spread-out Bragg peak can be reduced by using multiple
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treatment fields, rather than single fields. For example, if
a single field is used, a single spot of potential high RBE
would be delivered to the entire prescription dose rather
than a fraction of the full prescription dose.
Plan evaluation, similarly to photons, is based on target
coverage goals, OAR dose constraints, and plan quality
indices such as integral dose and dose conformality.
Frequently, the plans are normalized to the optimal CTV
coverage, but PTV coverage requirements certainly help facil-
itate photon and proton plan comparisons. It is important to
note that the treatment time can vary from 30 to 90 mins
depending on the number of isocenters and fields being treated
each day.20
Below is a summary of the treatment planning specifics
of PT planning, specifically DS technique:
(a) 3D-conformal treatment
● Manually laborious, forward planned
(b) CTV and normal structures are delineated in the
same way as for photons.
(c) For static geometries, the plan target is the CTV,
while when the treatment area is affected by breath-
ing motion an ITV that includes CTV motion is
derived from the 4D-CT.
(d) For lateral beam shaping, expansions for setup
uncertainty and inter-fractional anatomy variability
are applied to the CTV/ITV.
(e) Patient-specific beam collimators conform the dose
laterally to the CTV/ITV with a margin for penum-
bra (1 to 10 mm). Range compensators are
designed for each beam to conform the dose dis-
tally to the CTV/ITV. “Smearing” is applied to
compensate for proton range changes due to density
changes in the beam path.
(f) Additionally, along each beam, distal and prox-
imal margins are set to the CTV/ITV to compen-
sate for proton range uncertainties as described
above.18
(g) In the current practice of scatter techniques, mar-
gins to the CTV/ITV are assigned per beam:
● Collimator margins for the lateral penumbra are
set to the PTV with an expansion for setup
variations.
● Distal and proximal margins depend on depth of
the distal and proximal edges of the target. This
is “beam-specific planning target volume.”
(h) Beam selection and orientation depend on the
unique disease distribution for each patient.
(i) Whenever possible, the preference is to use anterior
or posterior fields, rather than both, to the same
targeted area in the mediastinum.
See below examples of treatment planning in a young
patient with classical HL using PT with and without DIBH
(Figures 1–3).
Pencil Beam Scanning (PBS)
PBS offers a dosimetric advantage over double scattering
technique with regard to conformality around OARs, par-
ticularly for irregularly shaped targets. PBS is useful when
the target volume varies markedly in depth, and also when
the target spans over a large field size. Consequently, PBS
solves many of the treatment planning complications of
DS by allowing irregular and non-contiguous targets with
homogeneous target coverage and improved sparing of
OARs. PBS allows for delivery of 3D conformal treat-
ments with 1 to 2 fields without the need for multiple
custom-built compensators and apertures, which can be a
laborious procedure.
PBS field sizes tend to be larger than DS field sizes,
thus larger targets can be easily planned. As noted above,
if requiring treatment to a large target with DS, matched
fields must be created (with separate apertures and com-
pensators), which can often result in hot or cold dosimetric
areas. Additionally, the “beam-on” time for PBS is often
longer than for DS technique, making it more difficult to
administer a DIBH method (if available). Also, there is
more skin sparing with PBS compared to DS, and thus,
overlapping beams on the skin are not a major concern.
For example, PBS is able to shape the proton beam to
conform to the shallow and deep aspects of the target, thus
allowing for a “skin-sparing” effect. In DS system, the
proton beam can only be shaped to conform to the deeper
shape of the target, thus precluding a skin sparing effect
for superficial targets. PBS beams are usually angled away
from each other to allow for improved robustness. It is
also important to note that the above-described margins for
both techniques do not protect against unpredictable,
uncommon changes that may occur during the course of
treatment such as disease progression, pleural effusions,
pneumonia (or pulmonary consolidation), or weight loss.
Overall, all of the available PT techniques are used to
maximize cure and minimize the morbidity of treatment,
and providers are encouraged to follow the current ILROG
guidelines for proton beam therapy in adult radiotherapy
programs.16 For this reason, a plan comparison between
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PT and a modern photon solution is strongly recommended
before treatment, in order to demonstrate the beneficial
role of protons. Indeed, it should be noted that the poten-
tial clinical benefit of PT over photon RT is greatly influ-
enced by the disease extension and localization. As an
example, some anatomical presentations as the lower ante-
rior mediastinum mostly benefit from a PT solution. It is
likely that if one encounters a case such as in Figure 4, in a
young patient with curable disease, PT would be of sig-
nificant dosimetric and clinical benefit.
Figure 1 Case: pre-chemotherapy PET/CT for 20 years old patient with Stage IIA cHL. Patients received ABVD x 4 cycles, achieving a complete metabolic response after 2
cycles (Deauville 3), confirmed after 4 cycles (Deauville 2). Consolidation radiotherapy was planned with a total dose of 30Gy in 15 fractions.
Figure 2 Comparative planning: proton vs photon using DIBH. Left: protons (DS) +DIBH; right: RapidArc+DIBH.
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Clinical Reports Of Proton Therapy
For Lymphomas
Modern radiotherapy for lymphomas combines smaller
fields (involved site radiotherapy, ISRT, and involved
node radiotherapy, INRT), lower doses and highly confor-
mal techniques compared to the past. Given the higher
conformal dose distribution achieved with protons, many
investigators have raised the issue of the potential
increased relapse rate, in particular at the field edge.
First, clinical reports were therefore focused on this
question, as the main scope was to demonstrate the ability
of PT to obtain the same cure rates of modern photon
techniques. With this background, University of Florida
conducted a phase II pilot study on 15 stage I–III HL
patients, treated with involved-node PT between 2009 and
2013.21 With a median follow-up of 37 months, the 3-year
relapse-free survival (RFS) rate was 93%, absolutely simi-
lar to the outcome obtained with modern photon radiother-
apy in HL. Some clinical reports were subsequently
published, with most of them focusing on HL patients
with mediastinal involvement. The Proton Collaborative
Group Registry reported on a cohort of 50 patients treated
with consolidation proton ISRT and followed-up prospec-
tively (median follow-up time: 21 months).22 Most patients
were adults (64%), with a high prevalence of mediastinal
involvement (93%) and of bulky lesions (65%). The overall
outcome was good, with a 2-year RFS of 85%. There were
only 3 relapses: two were infield, within bulky mediastinal
lesions treated with 21 Gy, and one was marginal, superior
to the treatment field and to the clinical target volume and
for such reason would have been missed with a photon plan
as well. Very recently, a collaborative group first reported
the clinical results of a cohort of 21 adult HL patients
treated with deep inspiration breath-hold PBS-PT.23 All
patients were treated at 30 Gy in 15 fractions. With a
median follow-up time of 24 months, no patient relapsed
and all were alive. Treatment was well tolerated and no
severe toxicities were reported.
Although most studies enrolled HL patients, few
reports on small series of NHL patients are available.
University of Florida first described their outcome with
PT in a group of 11 NHLs, which included patients
affected with a variety of different histologies.24 Three-
year PFS and OS were 91%, with only one case of in-field
relapse in a patient treated for a natural killer/T cell lym-
phoma. No severe toxicities (Grade >2) were reported.
Afterward, Plastaras et al25 reported their experience
with PT in a cohort of nodal NHLs with mediastinal
involvement or primary mediastinal B cell lymphomas.
Overall, 24 patients were enrolled, with a high predomi-
nance of bulky lesions at baseline (87%). The median
follow up was 28 months and 2-year PFS and OS were
87% and 96%, respectively. Only one patient relapsed in-
field and none had grade 2 or higher radiation pneumoni-
tis. A recent publication from a German group26 enrolled
Figure 3 Comparative planning proton vs photon in free-breathing. Left: protons (DS); Right: RapidArc.
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20 patients affected with either HL (9) or NHL (11). The
outcome was, again, impressive with a 2-year PFS and OS
of 95% and 100%, respectively. The toxicity profile was
good as well, with a good tolerance to PT and no events of
grade 3 or higher.
The adoption of PT is even more promising in the setting
of relapsed/refractory disease, when peri-transplant radia-
tion is frequently omitted despite its valuable effect for the
concerns related to toxicity –mainly grade 2–3 pneumonitis
– after photon RT. Tseng et al27 enrolled in a multi-institu-
tional study 51 patients treated with PT for a relapsed/
refractory HL or NHL. All patients were heavily pretreated
and one third received peri-transplant PT. With a median PT
dose of 36 Gy (range 25.2–54 Gy) and a median follow-up
of 21 months, the 2-year progression-free survival (PFS)
and overall survival (OS) were 69% and 87%, respectively.
Obviously, HL patients had a better outcome compared to
NHL patients in terms of both PFS (78% vs 46%) and OS
(88% vs 82%). Only 6 patients (12%) developed a sympto-
matic grade 2 pneumonitis (no grade 3> toxicity event
reported), which is lower compared to historical controls
treated with photon RT. These preliminary results, that need
to be confirmed in larger cohorts, seem to favor PT over
photon RT in this setting, given the more conformal dose
distribution of protons and ability to better spare fundamen-
tal organs at risk as lungs and heart.
Despite the brilliant clinical results, all the studies men-
tioned above included a small number of patients, mostly
within a mono-institutional accrual, and thus a careful
extrapolation is mandatory. To date, the largest multi-insti-
tutional case series of lymphoma patients treated with PT
was published by Hoppe et al28 in 2017. The authors
included 138 pediatric and adult HL patients. With a median
follow-up of 32 months, the 3-year RFS rate was 92% for all
Figure 4 When the target spans down in front of the heart, protons can be very useful. (A) Sagittal view; (B) axial view.
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(96% for adults, 87% for pediatric patients), with none
marginal relapse. The accompanying editorial for this
study29 celebrated the excellent clinical results, similar to
those obtained with modern photon radiotherapy in HL.
Interestingly, there were no marginal relapses potentially
related to the rapid dose fall-off of the Bragg peak. This
observation was extremely important, given that the com-
bination of steep dose-gradient techniques with the modern
definition of limited target volumes (INRT and ISRT) raises
many concerns on the potential increase of relapses. More
studies with similar or possibly larger numbers are manda-
tory to strengthen these preliminary observations and to
increase the robustness of the information on the role of
PT in lymphoma patients. Table 1 summarizes all clinical
studies investigating the role of PT in this setting.
Uncertainties Of Proton Therapy
The most relevant challenges associated with PT, com-
pared to photons, are the uncertainties related to the dif-
ferent beam penetration range in tissues and to the changes
in the magnitude of the relative biological effect (RBE)
along the beam path.16 Herein below, we briefly describe
these uncertainties and the possible ways to mitigate them.
Relative Biologic Effectiveness (RBE)
RT prescription and constraints are based on dose para-
meters and dose–response relationships, which are basi-
cally derived by photon therapy. Different radiation
modalities may produce different dose responses, and
this aspect is relevant also in the comparison between
photon (the reference radiation by definition) and protons.
This discrepancy is evaluated through the relative biologi-
cal effect (RBE), which is the ratio of the absorbed dose
that produces the same biological effect between photons
and protons.34 The currently used RBE in clinical practice
is 1.1, but some studies have demonstrated that this para-
meter depends on many factors as proton energy, dose per
fraction, tissue and cell type, oxygenation and other
aspects that may influence the radiosensitivity of the
tissue.35,36 Moreover, RBE estimation of protons is
derived by in vitro studies, but in vivo studies are still
missing.37 Furthermore, actual data suggest that RBE may
change along the beam path, with a significant increase at
the beam tail in the proximity of the Bragg peak. This
aspect is related to the increase of the linear energy trans-
fer (LET) of the proton beam at the distal edge and raises
many concerns on the estimation of the dose received by
the target of treatment and, particularly, by organs at risk
located in its close proximity. In fact, the increase in RBE
at the beam tail may extend the beam range by 2–4 mm,
depending on the depth in the target tissue and on the
beam energy.38 This leads to a potential extension of the
high-dose region beyond the target volume and may end
up in organs at risk located behind the tumor.39
Paradoxically, this aspect may lead to the creation of hot-
spots in those structures that should be better spared with
protons (i.e. heart and breasts) when treating mediastinal
lymphomas. Given that RBE-based or LET-based planning
is not available to date, precautions should be adopted to
protect healthy tissues as the use of multiple fields to dilute
the effect, or reduction of the physical dose to organs at
risk located in the proximity of the distal edge.16
Uncertainties Due To Density Variations
And Organ Motion
Protons are particle therapies with mass and, therefore,
density of the tissues and organs encountered by the
beam path greatly influences the dose deposited. Any
anatomic variation in term of position and size – of both
patient and tumor – could affect the dose distribution.
Particularly, the axial deviations may translate in range
uncertainties; in fact, the range of PT is related to every
single voxel of the planning imaging and any minimal
change of the patient anatomy (and consequently of the
mass density and of the related voxel) will modify the
range of all protons crossing that/those specific voxel.16,37
Strategies to mitigate this dosimetric uncertainty are
strongly recommended, through the adoption of tracking
techniques40 or a 4-dimensional CT scan to compensate
for organ motion (mainly lungs).41 Moreover, large mar-
gins should be applied to account for the uncertainties due
to the inevitable differences in tissue across the proton
track. A compensatory margin could be considered also
to “protect” very small and critical OARs as the coronary
arteries, whose physiologic movement during the cardiac
cycle is unavoidable.42 When the sparing of critical organs
is mandatory, all these issues should be kept in mind and a
comparative planning would be strongly recommended not
only between different PT plans, but also with modern and
highly conformed photon solutions as intensity-modulated
RT (IMRT) and optimized volumetric arc therapy
solutions.43 Indeed, in some particular anatomical situa-
tions (even in some patients with mediastinal involve-
ment), the gradual fall of the dose around the target
volume may favor IMRT, given the high risk of a “full-
Dovepress Ricardi et al
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dose” extension to the organs at risk with PT for all the
issues mentioned above.39 Therefore, patient selection is
fundamental to estimate who might benefit mostly from
the offer of a PT plan. A well-balanced planning compar-
ison with a modern and optimized photon RT solution29 is
thus mandatory, taking in to account PTV coverage and
doses received by organs at risk. Figure 5 shows a dose-
volume histogram, comparing a photon and a proton
solution.
“In Silico” Comparison Of The
Radiation Late Effects Between PT
And Modern Photon RT
In a current radiation treatment, the difference between
modern delivery techniques is characterized by a difference
in the spatial distribution of radiation dose. Therefore, in
lymphoma, there is a large variation in the normal tissue
exposure among patients who nominally receive the same
form of radiotherapy due to the individual differences in
field size as well as in anatomical site of disease. Also, late
effects most often occur decades following treatment and
the excess risks reported in the literature are consequences
of now outdated treatment regimens and should not be
extrapolated to patients of today. Instead, the choice of an
optimal treatment strategy can be guided by comparative
dose planning and modeling studies.
Fourteen studies have evaluated the difference in organ
at risk (OAR) exposure with involved node/site PT versus
photon therapy in lymphoma (Table 2 for an overview).
The studies compare PT delivered with either passive
scatter (6 studies) or pencil beam scanning (7 studies)
techniques to modern radiotherapy photon planning using
3-dimensional conformal RT (3DCRT, 12 studies) with
anteroposterior-posteroanterior fields as well as to more
conformal photon planning with IMRT (7 studies), volu-
metric modulated arc therapy (VMAT, 5 studies), or
Helical Tomotherapy (2 studies). Three recent studies44–46
have also compared the benefits of deep inspiration breath-
hold (DIBH) in different combinations with PT and IMRT.
Importantly, several aspects should be carefully con-
sidered in the individual publications: 1) The patient popu-
lation: what are the no. of patients, HL vs NHL histology,
children vs adults, clinical stage, and primary vs relapsed/
refractory disease, 2) Where is the target localized and
how it is defined? Upper vs lower mediastinal presentation
and initial vs residual post-chemotherapy disease, 3) Is
information provided on photon planning field set-up,
optimization priorities and plan evaluation? and 4) Do
the authors have any proton planning experience? Is
robustness and dose and range uncertainties accounted
for? Among the 14 studies, three include HL and non-
HL patients,26,46,47 one report only on pediatric patients,48
three include both primary and relapsed/refractory
Figure 5 Dose volume histogram (DVH), representing the dose per volume received by the target of treatment (PTV) and organs at risk (OARs). In detail, a comparison
between PT plan and IMRT plan with RapidArc for a male patient affected with mediastinal Hodgkin lymphoma. Horizontal axis: dose of radiation (cGy); vertical axis: total
structure volume (%).
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patients,49–51 five origin from centers without proton
facilities,45,52–55 and two provide very limited clinical
information.46,56 Also, two studies define the target
volume as residual disease following chemotherapy47,57
and cannot be said to adhere to the INRT/ISRT concept.
A summary of estimated doses to thoracic OARs in med-
iastinal lymphoma is provided in Table 3; however, due to
the caveats mentioned above, considerable uncertainties
apply for the reported absolute values.
The following sections focus on primary mediastinal
stage I–II HL where data are most robust. In free-breathing
(FB), the mean doses to the heart, lungs and female breasts
are estimated to decrease with PT compared to 3DCRT and
modern RT (mRT). Interestingly, with DIBH-mRT, the
estimated mean dose to the heart is even lower, almost
similar for the lungs, and higher for female breasts which
may be due to the low dose bath associated with rotational
therapy and/or that most comparative dose planning stu-
dies in PT prioritize the female breasts the highest during
planning. When PT is combined with DIBH, a further dose
reduction may be achieved, especially for the mean dose to
the heart, compared to FB-PT and DIBH-mRT. It is impor-
tant to mention that this comparison cannot consider the
differences in the high- and low-dose distributions
between the individual studies which are equally important
when choosing the optimal treatment plan. Also, all stu-
dies report large individual differences in dose estimates,
and the importance of individualized treatment planning is
highlighted universally.
The risk of late effects from modern treatment can
be estimated through normal tissue complication prob-
ability (NTCP) models which describe the probability of
a certain endpoint occurring as a function of radiation
dose. For INRT/ISRT, only one NTCP study has been
published,44 although, Knäusl et al48 calculate the organ
equivalent dose which is as a measure of the biological
effect of absorbed dose in pediatric patients. However,
many photon-based NTCP models have been published
to date for lymphoma patients.43,53,59–63 which can be
extrapolated to calculate the clinical significance of a
dosimetric benefit with PT. In the single PT-based mod-
eling study available to date,44 the estimated reduction
in life expectancy attributable to late effects from RT
(from heart failure, myocardial infarction, valvular heart
disease, lung and breast cancer) is quantified by the Life
Years Lost (LYL) measure which accounts for age at
exposure, patient sex, and the prognosis of the indivi-
dual late effects. The authors report a LYL of 2.1, 1.3,
0.9, and 0.7 with FB-mRT, FB-PT, DIBH-mRT, and
DIBH-PT, respectively, and the LYL is primarily driven
by the risk of death from lung cancer and valvular
disease. Interestingly, there is no significant difference
in the LYL for FB-PT vs DIBH-mRT and FB-PT vs
DIBH-PT, respectively. Again, modeling studies are
Table 3 Mean Dose [Gy] To Thoracic Organs At Risk. Reported Mean Doses Based On Results In42,50,51,53,56 For Early-Stage
Mediastinal HL And On Results In24,44,46,54 For Stage I–IV Primary Mediastinal Hodgkin/non-Hodgkin Lymphoma (including Pediatric
Patients) Are Normalized To A 30 Gy Prescription Dose And Weighted According To Number Of Patients In Each Publication. Data
Do Not Allow For Reporting Of Dosimetric Parameters Other Than Mean Dose
Heart Lungs Breasts Esophagus Thyroid
Early-stage mediastinal HL
FB-3DCRT 10.3 8.4 3.5 16.1 15.0
FB-mRT 8.9 10.0 5.5 16.1 19.0
FB-PT 7.2 6.8 1.4 13.9 15.1
DIBH-mRT 3.5 7.8 4.5 N/A N/A
DIBH-PT 1.6 5.6 1.6 N/A N/A
Stage I–IV mediastinal HL/NHL
FB-3DCRT 8.3 18.8 7.4 N/A N/A
FB-mRT 10.1 12.1 6.8 14.0 21.3
FB-PT 5.9 6.0 3.0 11.2 22.3
DIBH-mRT 11.4 9.4 4.4 18.0 24.4
DIBH-PT 7.2 5.7 2.1 14.5 22.2
Abbreviations: 3DCRT, 3-dimensional conformal radiotherapy; DIBH, deep inspiration breath-hold; FB, free-breathing; mRT, modern radiotherapy; N/A, not available; PT,
proton therapy.
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limited by the same uncertainties as are dose planning
studies as well as by the inherent simplifications of the
modeling situation.
Conclusion
PT is an attractive modern radiation modality, with unique
properties that may significantly reduce the dose to OARs
and potentially spare late toxicity compared to modern
photon techniques in patients affected with lymphomas, par-
ticularly for those patients with a mediastinal involvement.
However, the potential benefit is variable and is based on
individual factors as gender, age and disease distribution that
should be taken into account on a “case-by-case” accurate
analysis. Given the limited number of PT facilities, the addi-
tional costs of protons compared to photons, the few clinical
reports available to date and some pending issues concerning
the biological effect, and the physical properties, it seems
reasonable to offer a proton treatment to lymphoma patients
only after the achievement of a good competency in the field.
Lastly, a careful selection of patients who may benefit from
PT, after a proper plan comparison with modern photon
therapy, might be a significant step towards further optimized
and a more safe RT delivery in hematological diseases.
Disclosure
The authors report no conflicts of interest in this work
References
1. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is
equally effective and less toxic compared with extended-field radio-
therapy after four cycles of chemotherapy in patients with early- stage
unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the
German Hodgkin’s Lymphoma Study Group. J Clin Oncol.
2003;21:3601–3608.
2. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-
reduced involved-field radiotherapy in patients with early un- favor-
able Hodgkin’s lymphoma: final analysis of the German Hodgkin
Study Group HD11 trial. J Clin Oncol. 2010;28:4199–4206.
doi:10.1200/JCO.2010.29.8018
3. Viviani S, Zinzani PL, Rambaldi A, et al. Michelangelo Foundation;
Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo
Italiano Linfomi: ABVD versus BEACOPP for Hodgkin’s lymphoma
when high-dose salvage is planned. N Engl J Med. 2011;365:203–212.
doi:10.1056/NEJMoa1100340
4. Mounier N, Brice P, Bologna S, et al. Lymphoma Study Association
(LYSA): ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4
baseline): final results in stage III-IV low-risk Hodgkin lymphoma
(IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol.
2014;25:1622–1628. doi:10.1093/annonc/mdu189
5. Horner M, Ries L, Krapcho M, et al. SEER cancer statistics review,
1975–2014. National Cancer Institute. 2017 Available from: https://
seer.cancer.gov/csr/1975_2014/. Accessed September 21, 2019.
6. Rutenberg MS, Flampouri S, Hoppe BS. Proton therapy for Hodgkin
lymphoma. Curr Hematol Malig Rep. 2014;9:203–211. doi:10.1007/
s11899-014-0212-7
7. Aleman BM, van Den Belt-Dusebout AW, De Bruin ML, et al. Late
cardiotoxicity after treatment for Hodgkin lymphoma. Blood.
2007;109:1878–1886. doi:10.1182/blood-2006-07-034405
8. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-
response relationship for risk of coronary heart disease in survivors of
Hodgkin lymphoma. J Clin Oncol. 2015;34:235–243. doi:10.1200/
JCO.2015.63.4444
9. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second
cancer risk up to 40 years after treatment for Hodgkin’s lymphoma.
N Engl J Med. 2015;373:2499–2511. doi:10.1056/NEJMoa1505949
10. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-
directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med.
2015;372:1598–1607. doi:10.1056/NEJMoa1408648
11. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy
in early positron emission tomography-negative Stage I/II Hodgkin
lymphoma is associated with an increased risk of early relapse:
clinical results of the preplanned interim analysis of the randomized
EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2014;32:1188–1194.
doi:10.1200/JCO.2013.51.9298
12. Ho CK, Flampouri S, Hoppe BS. Proton therapy in the management
of lymphoma. Cancer J. 2014;20:387–392. doi:10.1097/PPO.00000
00000000076
13. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for
Hodgkin lymphoma: field and dose guidelines from the international
lymphoma radiation oncology group (ILROG). Int J Radiat Oncol
Biol Phys. 2014;89:854–862. doi:10.1016/j.ijrobp.2013.05.005
14. Rwigema JM, Lagendijk JA, van der Laan PH, et al. A model-based
approach to predict short-term toxicity benefits with proton therapy
for oropharyngeal cancer. Int J Radiat Oncol Biol Phys.
2019;104:553–562. doi:10.1016/j.ijrobp.2018.12.055
15. Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal
non-Hodgkin lymphoma – target definition and dose guidelines from the
international lymphoma radiation oncology group. Int J Radiat Oncol
Biol Phys. 2014;89:49–58. doi:10.1016/j.ijrobp.2014.01.006
16. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults
with mediastinal lymphomas: the International Lymphoma Radiation
Oncology Group guidelines. Blood. 2018;132:1635–1646. doi:10.11
82/blood-2018-03-837633
17. Edvardsson A, Kugele M, Alkner S, et al. Comparative treatment plan-
ning study for mediastinal Hosgkin’s lymphoma: impact on normal
tissue dose using deep inspiration breath hold proton and photon therapy.
Acta Oncol. 2019;58:95–104. doi:10.1080/0284186X.2018.1512153
18. Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and
tools for proton beam design for lung tumors. Int J Radiat Oncol Biol
Phys. 2001;49:1429–1438. doi:10.1016/s0360-3016(00)01555-8
19. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in
proton radiation therapy. Phys Med Biol. 1984;29:553–566.
doi:10.1088/0031-9155/29/5/008
20. Pacelli R, Caroprese M, Palma G, et al. Technological evolution of
radiation treatment: implications for clinical applications. Semin
Oncol. 2019; in press. doi:10.1053/j.seminoncol.2019.07.004
21. Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton
therapy in combined modality therapy for Hodgkin lymphoma:
results of a Phase 2 study. Int J Radiat Oncol Biol Phys.
2014;89:1053–1059. doi:10.1016/j.ijrobp.2014.04.029
22. Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care
and early outcomes for Hodgkin lymphoma: results from the Proton
Collaborative Group Registry. Acta Oncol. 2016;55:1378–1380.
doi:10.1080/0284186X.2016.1197422
23. Ntentas G, Dedeckova K, Andrlik M, et al. Clinical intensity modulated
proton therapy for Hodgkin lymphoma: which patients benefit the most?
Practical Rad Onc. 2019;9:179–197. doi:10.1016/j.prro.2019.01.006
24. Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS.
Proton therapy in the management of non-Hodgkin lymphoma. Leuk
Lymphoma. 2015;56:2608–2612. doi:10.3109/10428194.2015.101
4364
Ricardi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
OncoTargets and Therapy 2019:128044
25. Plastaras JP, Maity A, Flampouri S, et al. Bi-institutional report on
consolidative proton therapy after initial chemotherapy for mediast-
inal diffuse large B-cell and primary mediastinal large B-cell lym-
phomas [abstract]. Int J Radiat Oncol Biol Phys. 2018;102(S3):E350.
doi:10.1016/j.ijrobp.2018.07.1061
26. Konig L, Bougatf N, Horner-Rieber J, et al. Consolidative mediast-
inal irradiation of malignant lymphoma using active scanning proton
beams: clinical outcome and dosimetric comparison. Strahlenther
Onkol. 2019. doi:10.1007/s00066-019-01460-7
27. Tseng YD, Hoppe BS, Miller D, et al. Rates of toxicity and outcomes
after mediastinal proton therapy for relapsed/refractory lymphoma
[abstract]. Int J Radiat Oncol Biol Phys. 2017;99(S2):S62.
doi:10.1016/j.ijrobp.2017.06.155
28. Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton
therapy after chemotherapy for patients with Hodgkin lymphoma.
Ann Oncol. 2017;28:2179–2184. doi:10.1093/annonc/mdx287
29. Ricardi U, Dabaja B, Hodgson DC. Proton therapy in mediastinal
Hodgkin lymphoma: moving form dosimetric prediction to clinical
evidence. Ann Oncol. 2017;28:2049–2050. doi:10.1093/annonc/
mdx356
30. Winkfield KM, Gallotto S, Niemierko A, et al. Proton therapy for
mediastinal lymphomas: an 8-year single-institution report [abstract].
Int J Radiat Oncol Biol Phys. 2015;93:E461. doi:10.1016/j.ijrobp.
2015.07.1725
31. Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric
Hodgkin lymphoma. Pediatr Blood Cancer. 2016;63:1522–1526.
doi:10.1002/pbc.26044
32. Plastaras JP, Vogel J, Elmongy H, et al. First clinical report of pencil
beam scanned proton therapy for mediastinal lymphoma [abstract].
Int J Radiat Oncol Biol Phys. 2016;96:E497. doi:10.1016/j.ijrobp.
2016.06.1876
33. Dedeckova K, Mocikova H, Markova J, et al. T011: proton radio-
therapy for mediastinal Hodgkin lymphoma: single institution experi-
ence [abstract]. Haematologica. 2016;101:12–13.
34. Paganetti H, Giantsoudi D. Relative biologic effectiveness uncertain-
ties and implications for beam arrangements and dose constraints in
proton therapy. Semin Radiat Oncol. 2018;28:256–263. doi:10.1016/
j.semradonc.2018.02.010
35. Paganetti H. Relative biologic effectiveness (RBE) values for proton
beam therapy. Variations as a function of biological endpoint, dose,
linear energy transfer. Phys Med Biol. 2014;59:R419–R472. doi:10.
1088/0031-9155/59/22/R419
36. Cuaron JJ, Chang C, Lovelock M, et al. Exponential increase in
relative biological effectiveness along distal edges of proton Bragg
peak as measured by deoxyribonucleic acid double-strand breaks. Int
J Radiat Oncol Biol Phys. 2016;95:62–69. doi:10.1016/j.ijrobp.
2016.02.018
37. International Commission on Radiation Units and Measurements.
Prescribing, recording, and reporting proton-beam therapy. ICRU
Report 78. 1996.
38. Pagnetti H. Relating proton treatments to photon treatments via the
relative biological effectiveness – should we revise current clinical
practice? Int J Radiat Oncol Biol Phys. 2015;91:892–894. doi:10.
1016/j.ijrobp.2014.11.021
39. Dabaja BS, Mikhaeel G. In the battle between protons and photons
for hematologic malignancies, the patient must win. Int J Radiat
Oncol Biol Phys. 2015;95:43–45. doi:10.1016/j.ijrobp.2015.09.043
40. Eley JG, Newhauser WD, Ritcher D, Luchtenborg R, Saito N, Bert C.
Robustness of target dose coverage to motion uncertainties for
scanned carbon ion beam tracking therapy of moving tumors. Phys
Med Biol. 2015;60:1717–1740. doi:10.1088/0031-9155/60/4/1717
41. Eley JG, Newhauser WD, Luchtenborg R, Graeff C, Bert C. 4D
optimization of scanned ion beam tracking therapy for moving
tumors. Phys Med Biol. 2014;59:3431–3452. doi:10.1088/0031-
9155/59/13/3431
42. Levis M, De Luca V, Fiandra C, et al. Plan optimization for mediastinal
radiotherapy: estimation of coronary arteries motion with ECG-gated
cardiac imaging and creation of compensatory expansion margins.
Radioth Oncol. 2018;127:481–486. doi:10.1016/j.radonc.2018.04.014
43. Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures
in the optimization process of volumetric modulated arc therapy
techniques may reduce the risk of heart disease in Hodgkin’s lym-
phoma patients. Radioth Oncol. 2019;138:52–58. doi:10.1016/j.
radonc.2019.05.009
44. Rechner LA, MaraldoMV, Vogelius IR, et al. Life years lost attributable
to late effects after radiotherapy for early stage Hodgkin lymphoma: the
impact of proton therapy and/or deep inspiration breath hold. Radioth
Oncol. 2017;125:41–47. doi:10.1016/j.radonc.2017.07.033
45. Baues C, Marnitz S, Engert A, et al. Proton versus photon deep
inspiration breath hold technique in pateints with Hodgkin lymphoma
and mediastinal radiation. Radiat Oncol. 2018;13:122. doi:10.1186/
s13014-018-1066-2
46. Everett AS, Hoppe BS, Louis D, et al. Comparison of techniques for
involved-site radiation therapy in patients with lower mediastinal
lymphoma. Pract Radiat Oncol. 2019. doi:10.1016/j.prro.2019.05.009
47. Li J, Dabaja BS, Reed V, et al. Rationale for and preliminary results
of proton beam therapy for mediastinal lymphoma. Int J Radiat
Oncol Biol Phys. 2011;81:167–174. doi:10.1016/j.ijrobp.2010.05.007
48. Knausl B, Lutgendorf-Caucig C, Hopfgartner J, et al. Can treatment
of pediatric Hodgkin’s lymphoma be improved by PET imaging and
proton therapy? Strahlenther Onkol. 2013;189:54–61. doi:10.1007/
s00066-012-0235-8
49. Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node
proton therapy for stage I-IIIB mediastinal Hodgkin lymphoma: pre-
liminary dosimetric outcomes from a phase II study. Int J Radiat Oncol
Biol Phys. 2012;83:260–267. doi:10.1016/j.ijrobp.2011.06.1959
50. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to
cardiac structures using protons compared with 3DCRT and IMRT in
mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys.
2012;84:449–455. doi:10.1016/j.ijrobp.2011.12.034
51. Sachsman S, Hoppe BS, Mendenhall NP, et al. Proton therapy to the
subdiaphragmatic region in the management of patients with Hodgkin
lymphoma. Leuk Lymphoma. 2015;56:2019–2024. doi:10.3109/
10428194.2014.975802
52. Jørgensen AY, Maraldo MV, Brodin NP, et al. The effect on esopha-
gus after different radiotherapy techniques for early stage Hodgkin’s
lymphoma. Acta Oncol. 2013;52:1559–1565. doi:10.3109/
0284186X.2013.813636
53. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardi-
ovascular disease and secondary cancers with modern highly confor-
mal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Ann Oncol. 2013;24:113–118. doi:10.1093/annonc/mdt156
54. Maraldo MV, Brodin NP, Aznar MC, et al. Doses to carotid arteries
after modern radiation therapy for Hodgkin lymphoma: is stroke still
a late effect of treatment? Int J Radiat Oncol Biol Phys.
2013;87:297–303. doi:10.1016/j.ijrobp.2013.06.004
55. Maraldo MV, Brodin NP, Aznar MC, et al. Doses to head and neck
normal tissues for early stage Hodgkin lymphoma after involved node
radiotherapy. Radiother Oncol. 2014;110:441–447. doi:10.1016/j.
radonc.2013.09.027
56. Zeng C, Plastaras JP, James P, et al. Proton pencil beam scanning for
mediastinal lymphoma: treatment planning and robustness assess-
ment. Acta Oncol. 2016;55:1132–1138. doi:10.1080/0284186X.
2016.1191665
57. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of
three different involved nodal irradiation techniques for stage II
Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-
modulated radiotherapy, and three-dimensional proton radiotherapy.
Int J Radiat Oncol Biol Phys. 2009;75:1173–1180. doi:10.1016/j.
ijrobp.2008.12.048
Dovepress Ricardi et al
OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com
DovePress
8045
58. Horn S, Fournier-Bidoz N, Pernin V, et al. Comparison of passive-
beam, proton therapy, helical tomotherapy and 3D conformal radia-
tion therapy in Hodgkin’s lymphoma female patients receiving
involved-field or involved site radiation therapy. Cancer Radiother.
2016;20:98–103. doi:10.1016/j.canrad.2015.11.002
59. Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation
pneumonitis in patients receiving intensity modulated radiation ther-
apy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol
Biol Phys. 2015;92:175–182. doi:10.1016/j.ijrobp.2015.02.010
60. Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated
arc therapy versus 3d-CRT for early stage mediastinal Hodgkin
lymphoma without axillary involvement: a comparison of second
cancers and heart disease risk. Int J Radiat Oncol Biol Phys.
2015;92:161–168. doi:10.1016/j.ijrobp.2015.02.030
61. Aznar MC, Maraldo MV, Schut DA, et al. Minimizing late effects for
patients with mediastinal Hodgkin lymphoma: deep inspiration
breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys.
2015;92:169–174. doi:10.1016/j.ijrobp.2015.01.013
62. Brodin NP, Maraldo MV, Aznar MC, et al. Interactive decision-
support tool for risk-based radiation therapy plan comparison for
Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2014;88:433–
445. doi:10.1016/j.ijrobp.2013.10.028
63. Pinnix CC, Cella L, Andraos TY, et al. Predictors of hypothyroidism
in Hodgkin lymphoma survivors after intensity modulated versus 3-
dimensional radiation therapy. Int J Radiat Oncol Biol Phys.
2018;101:530–540. doi:10.1016/j.ijrobp.2018.03.003
OncoTargets and Therapy Dovepress
Publish your work in this journal
OncoTargets and Therapy is an international, peer-reviewed, open
access journal focusing on the pathological basis of all cancers,
potential targets for therapy and treatment protocols employed to
improve the management of cancer patients. The journal also
focuses on the impact of management programs and new therapeutic
agents and protocols on patient perspectives such as quality of life,
adherence and satisfaction. The manuscript management system is
completely online and includes a very quick and fair peer-review
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal
Ricardi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
OncoTargets and Therapy 2019:128046
